In the News
The New York Times: Jennifer Doudna, a Pioneer Who Helped Simplify Genome Editing
As a child in Hilo, one of the less touristy parts of Hawaii, Jennifer A. Doudna felt out of place. She had blond hair and blue eyes, and she was taller than the other kids, who were mostly of Polynesian and Asian descent.
TIME: The 100 Most Influential People
No one, not even a bacterium, likes being infected by a virus, and early in evolution, bacteria developed a way to destroy viruses with exquisitely precise attacks. Very recently, Emmanuelle Charpentier and Jennifer Doudna figured out the inner workings of this bacterial self-protection, and then, in a tour de force of elegant deduction and experiment, they developed a plug-and-play version of that approach.
Xconomy: Doudna’s Caribou Bio Raises $11M To Expand Uses For Gene Editing Tech
Caribou Biosciences, one of the biotech startups working to advance a much-watched new technology for precise gene editing, announced today it has raised an $11 million Series A round from venture capital firms and Swiss drug giant Novartis.
FierceBiotech: Novartis steps in to help bankroll CRISPR-Cas9 pioneer Caribou
Pharma heavyweight Novartis has stepped in to help bankroll Berkeley, CA-based Caribou Biosciences, one of the upstart leaders in the race to develop the cutting-edge CRISPR-Cas9 gene editing technology.
Nature Biotechnology: Nature Biotechnology's academic spinouts of 2014
Ventures focusing on drug testing or therapies against rare disease, cancer, gastrointestinal disease, fibrosis and pain are among those selected by the editors in 2014's crop of startups.